Edition:
United States

Abcam PLC (ABCA.L)

ABCA.L on London Stock Exchange

1,345.00GBp
5:20am EDT
Change (% chg)

-12.00 (-0.88%)
Prev Close
1,357.00
Open
1,362.00
Day's High
1,368.89
Day's Low
1,330.00
Volume
40,383
Avg. Vol
411,984
52-wk High
1,426.00
52-wk Low
946.77

Chart for

About

Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company's purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in... (more)

Overall

Beta: 0.52
Market Cap(Mil.): £2,760.52
Shares Outstanding(Mil.): 205.04
Dividend: 3.42
Yield (%): --

Financials

  ABCA.L Industry Sector
P/E (TTM): 46.16 28.91 32.89
EPS (TTM): 0.29 -- --
ROI: 18.47 13.55 13.14
ROE: 19.71 15.38 15.15

BRIEF-Abcam Says Proposal Made To Horizon Discovery Regarding Possible Offer For Horizon Has Been Rejected

* MADE A PROPOSAL TO BOARD OF HORIZON DISCOVERY IN RELATION TO A POSSIBLE OFFER FOR HORIZON DISCOVERY AT A VALUE OF 181P PER HORIZON DISCOVERY SHARE

May 02 2018

BRIEF-Abcam Posts HY Pretax Profit Of 32.8 Mln STG

* H1 ‍TOTAL REVENUE GROWTH OF 9.8% ON A REPORTED BASIS TO £112.5M​

Mar 05 2018

UK's Abcam signs licensing deal with Roche; shares rise

British biotechnology firm Abcam Plc said on Monday it signed a deal with Roche Holding AG to get rights to a portfolio of the Swiss drugmaker's research products in its life science division.

Jan 22 2018

UK's Abcam signs licensing deal with Roche; shares rise

Jan 22 British biotechnology firm Abcam Plc said on Monday it signed a deal with Roche Holding AG to get rights to a portfolio of the Swiss drugmaker's research products in its life science division.

Jan 22 2018

BRIEF-Abcam Says Entered Into License Agreement With Roche​

* ‍HAS ENTERED INTO A DEFINITIVE LICENSE AGREEMENT WITH ROCHE​

Jan 22 2018

BRIEF-Abcam Says Signed Exclusive License Agreement with Roche

* ‍HAS ENTERED INTO A DEFINITIVE LICENSE AGREEMENT WITH ROCHE​

Jan 22 2018

Earnings vs. Estimates